Form 8-K - Current report:
SEC Accession No. 0001213900-22-021542
Filing Date
2022-04-26
Accepted
2022-04-26 09:20:08
Documents
15
Period of Report
2022-04-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT FILING ea158768-8k_citius.htm   iXBRL 8-K 26064
2 PRESS RELEASE DATED APRIL 24, 2022. ea158768ex99-1_citius.htm EX-99.1 10907
3 GRAPHIC image_001.jpg GRAPHIC 4477
  Complete submission text file 0001213900-22-021542.txt   263417

Data Files

Seq Description Document Type Size
4 XBRL DEFINITION FILE ctxr-20220426_def.xml EX-101.DEF 26560
5 XBRL LABEL FILE ctxr-20220426_lab.xml EX-101.LAB 36574
6 XBRL PRESENTATION FILE ctxr-20220426_pre.xml EX-101.PRE 25184
7 XBRL SCHEMA FILE ctxr-20220426.xsd EX-101.SCH 3663
9 EXTRACTED XBRL INSTANCE DOCUMENT ea158768-8k_citius_htm.xml XML 5339
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 22851999
SIC: 2834 Pharmaceutical Preparations